Nebula Research & Development LLC Buys New Shares in DaVita Inc. (NYSE:DVA)

Nebula Research & Development LLC purchased a new stake in DaVita Inc. (NYSE:DVA) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,886 shares of the company’s stock, valued at approximately $432,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Te Ahumairangi Investment Management Ltd raised its holdings in DaVita by 1.0% in the third quarter. Te Ahumairangi Investment Management Ltd now owns 48,137 shares of the company’s stock valued at $7,846,000 after acquiring an additional 500 shares in the last quarter. Tidal Investments LLC increased its position in shares of DaVita by 45.2% in the 3rd quarter. Tidal Investments LLC now owns 5,688 shares of the company’s stock valued at $932,000 after purchasing an additional 1,771 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of DaVita by 134.6% in the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock valued at $8,885,000 after purchasing an additional 31,502 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after purchasing an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DaVita stock opened at $141.45 on Wednesday. The firm’s fifty day simple moving average is $146.13 and its 200-day simple moving average is $155.01. DaVita Inc. has a 12 month low of $131.27 and a 12 month high of $179.60. The stock has a market capitalization of $11.32 billion, a price-to-earnings ratio of 13.17, a PEG ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on DVA shares. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Barclays boosted their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.